Why Idexx Labs Stock Rocketed Higher This Week

Shares of leading pet healthcare diagnostics provider Idexx Laboratories (NASDAQ: IDXX) were up by 9% this week as of 4 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence.

Idexx Labs reported fourth-quarter earnings Monday morning that surpassed analysts' expectations for revenue and earnings per share (EPS).

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »

A strong Q4 and even better guidance for 2025

Idexx delivered revenue and EPS growth of 6% and 13% in Q4, but its guidance appears to have caught the market's attention. Looking ahead to 2025, management expects the company to grow sales by 4% to 7%, while EPS is projected to jump between 10% and 15%.

While these may not seem like incredible results, this growth is exceptional, considering that veterinary visits per practice have declined for 12 consecutive quarters. After pulling forward growth during the pandemic, the veterinary industry has yet to return to normal, making Idexx's Q4 results and guidance reassuring for investors.

The next chapter of Idexx's growth story?

Idexx operates using a razor-and-blades business model. It installs diagnostic instruments at veterinary clinics and then generates recurring revenue from the equipment.

Once these instruments are in place, the company collects recurring revenue from consumables, reference lab diagnostic assistance, and consulting services. These recurring sales equal 79% of Idexx's total revenue and give the company very steady financials from year to year.

The company will launch its newest "razor" -- the Idexx inVue Dx cellular analyzer -- in March this year, potentially starting a new wave of growth. This new instrument can detect canine lymphoma early and could expand to most cancer types within three years, according to management.

Trading at 43 times earnings, Idexx trades at a premium valuation, but I believe it remains a once-in-a-decade opportunity, even after rising this week.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $323,686!*
• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $44,026!*
• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $545,283!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Learn more »

*Stock Advisor returns as of February 3, 2025

Josh Kohn-Lindquist has positions in Idexx Laboratories. The Motley Fool recommends Idexx Laboratories. The Motley Fool has a disclosure policy.